Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 29
 
Share:
Send email
Share:
Original paper

Real-world outcomes of immune checkpoint inhibitor monotherapy in later lines of recurrent/metastatic cervical cancer – evidence from a rescue access program in Poland

Renata Pacholczak-Madej
1
,
Maja Lisik-Habib
2, 3
,
Radosław Mądry
4
,
Monika Szarszewska
4
,
Zuzanna Borysiewicz
5
,
Katarzyna Gabalewicz
6
,
Ewa Iwańska
1
,
Wiktor Szatkowski
1
,
Mirosława Puskulluoglu
7
,
Jerzy Jakubowicz
1
,
Pawel Blecharz
1

  1. Department of Gynaecological Oncology, Maria Skłodowska-Curie National Institute of Oncology, Kraków, Poland
  2. Department of Proliferative Diseases, Copernicus Memorial Hospital, Łódź, Poland
  3. Comprehensive Cancer Centre and Traumatology, Łódź, Poland
  4. Department of Gynecological Oncology, Poznań University of Medical Sciences, Poznań, Poland
  5. Department of Oncology and Chemotherapy, Provincial Integrated Hospital, Elbląg, Poland
  6. Lower Silesian Oncology, Pulmonology and Haematology Centre, Wrocław, Poland
  7. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
Contemp Oncol (Pozn) 2025; 29 (4): 384–392
DOI: https://doi.org/10.5114/wo.2025.155581
Online publish date: 2025/10/28
Article files
- Real-world outcomes.pdf  [0.10 MB]
- Real-world outcomes - Supplementary.pdf  [0.03 MB]
Get citation
 
PlumX metrics:
 
1. Quinn M, Benedet J, Odicino F, Maisonneuve P, Beller U, Cresman W, et al. Carcinoma of the cervix uteri. Int J Gynecol Obstet 2006; 95: S431-03.
2. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N En J Med 2014; 370: 734-743.
3. Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasega- wa K, et al. First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol 2023; 41: 5505-5511.
4. Marth C, Landoni F, Mahner S, Mccormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: 72-83.
5. Management of recurrent or metastatic cervical cancer – UpToDate [Internet]. Available from: https://www-1uptodate -1com- 1v540453800ab.hanproxy.cm-uj.krakow.pl/contents/management-of-recurrent-or-metastatic-cervical-cancer?search=metastatic%20cervical%20cancer&source=search_result&selectedTitle=1%7E51&usage_type=default&display_rank=1#H4272956502 (accessed: 5.01.2025).
6. Sznurkowski JJ, Bodnar L, Szylberg Ł, Żółciak-Siwińska A, Dańska- Bidzińska A, Klasa-Mazurkiewicz D, et al. The Polish Society of Gynecological Oncology Guidelines for the diagnosis and treatment of cervical cancer (v2024.0). J Clin Med 2024; 13: 4351.
7. Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. Available from: www.fda.gov/medwatch (accessed: 5.01.2025).
8. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019; 37: 1470-1478.
9. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, et al. Survival with cemiplimab in recurrent cervical cancer. N En J Med 2022; 386: 544-555.
10. Cemiplimab i summary of product characteristics.Available from: https://ec.europa.eu/health/documents/community-register/ 2019/20190628145113/anx_145113_pl.pdf.
11. Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derk- sen JWG, Suijkerbuijk KPM, et al. ESMO Guidance for Reporting Oncology real-World evidence (GROW). Ann Oncol 2023; 34: 1097-1112.
12. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132-137.
13. Pembrolizumab. Summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.
14. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 5 behalf of the ESMO Guidelines Committee. Ann Oncol 2022; 33: 1217-1238.
15. Choi MC, Kim YM, Lee JW, Lee YJ, Suh DH, Lee SJ, et al. Real-world experience of pembrolizumab monotherapy in patients with recurrent or persistent cervical cancer: a Korean multi-center retrospective study (KGOG1041). Cancers 2020; 12: 3188.
16. Hasegawa K, Takahashi S, Ushijima K, Okadome M, Yonemori K, Yokota H, et al. Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer. Cancer Med 2024; 13: e70236.
17. Alholm Z, Monk BJ, Ting J, Pulgar S, Boyd M, Sudharshan L, et al. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: a community oncology-based analysis. Gynecol Oncol 2021; 161: 422-428.
18. Miller KM, Filippova OT, Hayes SA, Abu-Rustum NR, Aghajanian C, Broach V, et al. Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecol Oncol Rep 2021; 37: 100831.
19. Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, et al. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: the MITO 44 study. Eur J Cancer 2024; 203: 114039.
20. Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, et al. Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Eur J Cancer 2025; 216: 115146.
21. Qi L, Li N, Lin A, Wang X, Cong J. Efficacy and safety of pembrolizumab on cervical cancer: a systematic review and single-arm meta-analysis. Front Oncol 2022; 12: 910486.
22. Shaibu Z, Yang F, Ting L, Dzidula L, Yusuf AE, Chen Z, et al. Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis. Contemp Oncol 2024; 28: 183-190.
23. Djuraev FM, Abdujapparov AS. Cemiplimab in treatment of metastatic and recurrent cervical cancer. ESMO Open 2024; 9: 103530.
24. Pacholczak-Madej R, Drobniak A, Stokłosa Ł, Bidas A, Dobrzańska J, Grela-Wojewoda A, et al. Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland. BMC Cancer 2024; 24: 1-11.
25. Pacholczak-Madej R, Grela-Wojewoda A, Puskulluoglu M, Lom- part J, Las-Jankowska M, Krawczak K, et al. Early effects of nivolumab and ipilimumab combined immunotherapy in the treatment of metastatic melanoma in Poland: a multicenter experience. Biomedicines 2022; 10: 2528.
26. Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, Ziętek M, Czarnecka AM, Piejko K, et al. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. Immunotherapy 2021; 13: 297-307.
27. Cybulska-Stopa B, Piejko K, Pacholczak R, Domagała-Haduch M, Drosik-Kwaśniewska A, Rolski J, et al. Real-world treatment practice in patients with advanced melanoma. Contemp Oncol (Pozn) 2020; 24: 118-124.
28. Pacholczak-Madej R, Lisik-Habib M, Mądry R, Szarszewska M, Borysiewicz Z, Gabalewicz K, et al. Thyroid disorders as predictors of cemiplimab efficacy in r/mCC: real-world evidence from Poland. Front Immunol 2025; 16: 1604826.
29. Ahmed F, Shah Z, Khan I, Bhatnagar A, Garimella R, Mishra S, et al. 567 Efficacy of checkpoint inhibitor immunotherapy drug pembrolizumab (KEYTRUDA) for treatment of advanced cervical cancer. Int J Gynecol Cancer 2021; 31: A32.1-A32.
30. Chen W, Zhang N, He Z, Li Q, Wang Y, Lou W, et al. The efficacy of immune checkpoint inhibitors on low PD-L1 cervical cancer: a meta-analysis. Health Sci Rep 2024; 7: e2069.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.